ALKERMES | ALKS - 应收帐款人

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.56B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	应收帐款人	更改		日
AbbVie	USD 12.48B		110M	2026-03
Acadia Pharmaceuticals	USD 166.33M		17.95M	2026-06
ALKERMES	USD 456.48M		48.85M	2026-06
Amgen	USD 10.23B		1.09B	2026-06
Biogen	USD 1.79B		76.6M	2026-03
BioMarin Pharmaceutical	USD 1.06B		157.13M	2026-06
Bristol-Myers Squibb	USD 13.83B		535M	2026-06
Coherus Biosciences	USD 18.42M		232.08M	2025-12
Eli Lilly	USD 23.48B		2.3B	2026-06
Gilead Sciences	USD 5.06B		314M	2026-06
Heron Therapeutics	USD 89.59M		8.54M	2025-12
Ionis Pharmaceuticals	USD 58.84M		15.16M	2026-06
J&J	USD 22.54B		1.21B	2026-03
Malin Corporation	EUR 500K		300K	2024-12
Merck	USD 12.21B		435M	2026-03
Nektar Therapeutics	USD 3.6M		1.82M	2026-03
Neurocrine Biosciences	USD 887M		118.9M	2026-06
Otsuka Holdings	JPY 595.39B		58.02B	2026-06
Ovoca Bio	EUR 53K		14K	2025-12
Pfizer	USD 16.19B		19M	2026-06
Regeneron Pharmaceuticals	USD 6.57B		834.4M	2026-06
Vertex Pharmaceuticals	USD 2.13B		138.2M	2026-06